Phanes Therapeutics’ PT217 Secures the US FDA’s Fast Track Designation for Neuroendocrine Prostate Cancer (NEPC)
Shots:
- The US FDA has granted fast track designation to PT217 for treating metastatic de novo or treatment-emergent neuroendocrine prostate cancer (NEPC)
- PT217 is being investigated under P-I/II (SKYBRIDGE) trial for its safety, tolerability, pharmacokinetics and preliminary efficacy in patients with advanced or refractory cancers with DLL3 expression and another P-I trial in China (CTR20242720)
- PT217 is a first-in-class bispecific antibody targeting DLL3 & CD47 and being developed for SCLC & neuroendocrine carcinoma (NEC), incl. NEPC. Phanes has also partnered with Roche to study it in combination with atezolizumab
Ref: Phanes | Image: Phanes
Related News:- Phanes Therapeutics Reports the First Patient Dosing with PT886 in P-I/II Study for Pancreatic and Gastric Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
